Human Genome Epidemiology Literature Finder
|
Records 1 - 7 (of 7 Records) |
| Query Trace: Stomatitis and PIK3CA[original query] |
|---|
| A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR-Tyrosine Kinase Inhibitors. Cancer research and treatment : official journal of Korean Cancer Association 2016 May . Han Ji-Youn, Lee Ki Hyeong, Kim Sang-We, Min Young Joo, Cho Eunkyung, Lee Youngjoo, Lee Soo-Hyun, Kim Hyae Young, Lee Geon Kook, Nam Byung Ho, Han Hyesun, Jung Jina, Lee Jin S |
| Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors. Cancer discovery 2017 Mar . Juric Dejan, Krop Ian, Ramanathan Ramesh K, Wilson Timothy R, Ware Joseph A, Sanabria Bohorquez Sandra, Savage Heidi, Sampath Deepak, Salphati Laurent, Lin Ray, Jin Huan, Parmar Hema, Hsu Jerry Y, Von Hoff Daniel D, Baselga Jo |
| LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases. Breast cancer research and treatment 2018 Jun . Van Swearingen Amanda E D, Siegel Marni B, Deal Allison M, Sambade Maria J, Hoyle Alan, Hayes D Neil, Jo Heejoon, Little Paul, Dees Elizabeth Claire, Muss Hyman, Jolly Trevor, Zagar Timothy M, Patel Nirali, Miller C Ryan, Parker Joel S, Smith J Keith, Fisher Julie, Shah Nikita, Nabell Lisle, Nanda Rita, Dillon Patrick, Abramson Vandana, Carey Lisa A, Anders Carey |
| Phase I/II clinical trial of everolimus combined with gemcitabine/cisplatin for metastatic triple-negative breast cancer. Journal of Cancer 2018 9 (7): 1145-1151. Park In Hae, Kong Sun-Young, Kwon Youngmee, Kim Min Kyeong, Sim Sung Hoon, Joo Jungnam, Lee Keun Se |
| Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor-positive advanced breast cancer. Cancer science 2018 3 109 (5): 1592-1601. Tamura Kenji, Kodaira Makoto, Shimizu Chikako, Yonemori Kan, Yunokawa Mayu, Shimomura Akihiko, Kobayashi Takayuki, Nakano Kenji, Tomomatsu Junichi, Ito Yoshinori, Tanaka Jun, Kuriki Hiroshi, Gu Zhaodi, Takahashi Shun |
| FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2020 11 27 (7): 1842-1849. Narayan Preeti, Prowell Tatiana M, Gao Jennifer J, Fernandes Laura L, Li Emily, Jiang Xiling, Qiu Junshan, Fan Jianghong, Song Pengfei, Yu Jingyu, Zhang Xinyuan, King-Kallimanis Bellinda L, Chen Wei, Ricks Tiffany K, Gong Yutao, Wang Xing, Windsor Katherine, Rhieu Steve Y, Geiser Gerlie, Banerjee Anamitro, Chen Xiaohong, Reyes Turcu Francisca, Chatterjee Deb K, Pathak Anand, Seidman Jeffrey, Ghosh Soma, Philip Reena, Goldberg Kirsten B, Kluetz Paul G, Tang Shenghui, Amiri-Kordestani Laleh, Theoret Marc R, Pazdur Richard, Beaver Julia |
| Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2024 9 JCO2400110. Komal L Jhaveri, Melissa K Accordino, Philippe L Bedard, Andrés Cervantes, Valentina Gambardella, Erika Hamilton, Antoine Italiano, Kevin Kalinsky, Ian E Krop, Mafalda Oliveira, Peter Schmid, Cristina Saura, Nicholas C Turner, Andrea Varga, Sravanthi Cheeti, Stephanie Hilz, Katherine E Hutchinson, Yanling Jin, Stephanie Royer-Joo, Ubong Peters, Noopur Shankar, Jennifer L Schutzman, Dejan Jur |
- Page last reviewed:Feb 1, 2024
- Content source: